Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
Last trade$1.84
Day change+$0.125 (+7.31%)
Day range$1.64 – $1.85
Volume329,255
Market cap$57M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$57.27M
Price / earnings
0.55×
Price / book
0.35×
Price / sales
0.82×
EV / sales
-1.43×
EV / EBITDA
4.25×
Profitability
Earnings per share
$3.09
Return on assets
32.64%
Return on equity
62.97%
Dividend yield
0.58%
Liquidity and leverage
Debt / equity
0.24×
Current ratio
3.96×
Quick ratio
3.83×
Cash ratio
3.17×
Cash flow
Price / cash flow
0.45×
Price / free cash flow
0.46×
Free cash flow
$125.84M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FBIO, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$18.72M
$15.92M
$18.09M
$17.03M
$16.41M
$13.14M
$15.12M
$14.63M
Cost of revenue
$6.14M
$6.22M
$5.44M
$5.76M
$4.94M
$4.79M
$4.68M
$4.47M
Gross profit
$12.58M
$9.7M
$12.65M
$11.27M
$11.47M
$8.35M
$10.44M
$10.16M
Selling, general and administrative
$20.81M
$15.89M
$14.73M
$17.42M
$38.76M
$25.66M
$26.86M
$21.99M
Research and development
$805K
$540K
-$367K
$208K
$8.13M
$3.94M
$9.69M
$9.45M
Total operating expenses
$22.58M
$17.56M
$15.43M
$18.69M
$47.95M
$30.67M
$34.28M
$32.25M
Operating income
-$10.01M
-$7.86M
-$2.78M
-$7.42M
-$36.47M
-$22.32M
-$23.84M
-$22.1M
Interest expense
-$1.48M
-$3.37M
-$2.04M
-$2.74M
-$2.52M
-$2.81M
-$2.59M
-$6.21M
Income before taxes
$922K
$142.29M
-$6.21M
$8.85M
-$11.65M
-$24.69M
-$25.98M
-$26.63M
Income taxes
$320K
$5.13M
-$816K
$26K
$0
$0
$336K
$69K
Net income
$602K
$137.16M
-$5.4M
$8.83M
-$11.65M
-$24.69M
-$26.32M
-$26.69M
Net income attributable to common shareholders
-$2.48M
$108.37M
-$6.2M
$3.68M
$13.36M
-$12.72M
-$9.65M
-$15.04M
EBITDA
-$8.94M
-$6.64M
-$1.62M
-$6.26M
-$35.32M
-$21.13M
-$21.42M
-$21.14M
Basic earnings per share
-$0.08
$3.44
-$0.20
$0.13
$0.50
-$0.48
-$0.35
-$0.76
Diluted earnings per share
-$0.08
$2.82
-$0.28
$0.11
$0.45
-$0.48
-$0.35
-$0.76
Recent news
Company coverage with links to the original publishers.
Fortress Biotech announced that CEO Lindsay A. Rosenwald will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will be available on-demand starting September 11, 2026, with one-on-one meetings scheduled for September 14-16, 2026. The company continues to advance its portfolio of marketed pharmaceutical products and development programs across oncology, dermatology, and rare diseases through partnerships with leading academic and biopharmaceutical institutions.
Fortress Biotech and its subsidiary Cyprium Therapeutics received a Complete Response Letter from the FDA regarding the New Drug Application for CUTX-101, citing manufacturing facility cGMP deficiencies, which negatively impacted the company's stock price.
Fortress Biotech's subsidiary Cyprium Therapeutics received a Complete Response Letter from the FDA for CUTX-101, a drug intended to treat Menkes disease. Sentynl Therapeutics, which assumed responsibility for the drug, plans to address manufacturing facility cGMP deficiencies and resubmit the New Drug Application.
Fortress Biotech announced the closing of the sale of its subsidiary Checkpoint Therapeutics to Sun Pharmaceutical Industries Limited. The transaction will generate approximately $28 million for Fortress and a 2.5% royalty on net sales of Checkpoint's FDA-approved drug UNLOXCYT.
Fortress Biotech, an innovative biopharmaceutical company, announced the FDA approval of its drug Emrosi for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway. The company also announced a strategic collaboration with Partex NV to accelerate asset identification and evaluation using Partex's proprietary AI platform.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.